Clinical Management of the Transplant Patient
What the exam tests
Clinical management questions ask you to connect a patient's current numbers and symptoms to a decision. Core concepts: immunosuppression pharmacology (calcineurin inhibitors, antimetabolites, mTOR inhibitors, corticosteroids, induction agents), therapeutic drug monitoring, infection prophylaxis, fluid and electrolyte management, blood pressure and glycemic control, and recognition of rejection versus drug toxicity versus infection.
Traps
- Level vs. dose. Tacrolimus and cyclosporine are monitored by trough level, not dose. A "normal" dose can be toxic in one patient and subtherapeutic in another. Questions often give a level and ask for the next action.
- Calcineurin inhibitor nephrotoxicity mimics rejection. Rising creatinine with a high tacrolimus level points to toxicity; with a low level or new donor-specific antibodies, think rejection. Biopsy is the tiebreaker.
- Timing of complications. Early (weeks) favors technical/surgical and ischemic issues; intermediate (months) favors infection (CMV, Pneumocystis) and acute rejection; late favors chronic rejection and malignancy.
- Prophylaxis is not treatment. Trimethoprim-sulfamethoxazole covers Pneumocystis and some urinary pathogens; it does not cover CMV. Know which drug covers which organism.
- Steroid stress dosing. Patients on chronic corticosteroids may need stress-dose steroids perioperatively; missing this is a classic distractor.
Rule of thumb
When a transplant patient's creatinine rises, ask three questions in order: Is the drug level high? Is there an infection? Are there donor-specific antibodies? Each points to a different next step.
Worked example
A kidney recipient 6 months out has creatinine up from 1.2 to 1.9 mg/dL, tacrolimus trough 14 ng/mL (target 5–8), no fever. The most likely cause is calcineurin inhibitor toxicity, and the next step is dose reduction with repeat level-not empiric antirejection therapy.